Evaluating the HPV Vaccine: A Call for Caution
Human Papillomavirus (HPV) vaccination has been widely promoted as a preventive measure against cervical cancer. However, a careful examination of current research and reported outcomes suggests that the benefits of this vaccine are not as they are portrayed, while the risks and unintended consequences warrant serious consideration.
1. Questionable Effectiveness of HPV Vaccines
Despite broad marketing optimism, the clinical efficacy of HPV vaccines in preventing cervical cancer has not been definitively demonstrated. According to Tomljenovic et al (2012), the enthusiasm around HPV vaccines relies heavily on surrogate markers rather than direct evidence of cancer prevention. Their review highlights that, to date, clinical trials have not conclusively shown that vaccination has prevented a single case of cervical cancer or death from the disease. This calls into question the assumptions underpinning widespread vaccination policies and emphasizes the need for ongoing, rigorous long-term studies.
2. Risks Associated with HPV Vaccination
The safety profile of the HPV vaccine requires thorough scrutiny. Some studies have identified a concerning trend where vaccinated women might experience an increased risk—estimated between 3% to 6%—of acquiring high-risk HPV infections compared to unvaccinated peers (Wright et al., 2012). Additionally, the vaccine manufacturer Merck has noted that for women previously exposed to HPV strains included in the vaccine, there is a 45% higher risk of developing precancerous lesions post-vaccination. Such findings underscore that vaccination is not without significant risk factors. The large scale importance of vaccine safety should always be considered differently than with typical medications. Only people who are sick with some kind of condition take medication. They are already facing some level of risk from the condition, so taking a medication that poses a new risk might be worth the risk to that person. A vaccine however, is given to a healthy person who is facing no such risk from an active condition. Thus a vaccine intervention that poses a new risk -necessarily should be weighed much more heavily.
3. Potential for Greater Harm Through Widespread Vaccination
Public health data reveals that HPV infection is extremely common; approximately 50% of sexually active adults currently carry at least one strain, and nearly all will encounter HPV at some point (CDC, 2013). Importantly, 99.5% of these individuals never experience clinical symptoms or health issues, with 90% clearing the infection naturally via immune response.
By contrast, adverse events following HPV vaccination have been reported with concerning frequency. The Vaccine Adverse Event Reporting System (VAERS) has logged hundreds of serious reports, including deaths, disabilities, and hospitalizations.
To be specific, as of July 25 2025 the number of correlated adverse events are as follows:
17,126 Emergency room visits
8,176 Hospitalizations
3,900 Permanent Disabilities
1,205 Life Threatening Reactions
644 Deaths.
… of previously healthy people.
Conclusion
The decision to recommend and receive HPV vaccination should be grounded in transparent, evidence-based evaluation of both benefit and risk. If you want additional resources or care to discuss things further, you are welcome to contact us.
References
- Tomljenovic L, Shaw CA, Spinosa JP. Human Papillomavirus (HPV) Vaccines as an Option for Preventing Cervical Malignancies: (How) Effective and Safe? Curr Pharm Des. 2012 Sep 24.
- Wright TC, Stoler MH, Behrens CM, et al. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol 2012;206:46.e1-11. FDA.gov Gardasil™ HPV Quadrivalent Vaccine May 18, 2006 VRBPAC Meeting (PDF)
- The Vaccine Adverse Event Reporting System (VAERS) Results. Data current as of 07/25/2025
